Implementation of artificial intelligence approaches in oncology clinical trials: A systematic review

Funding Sponsor

American University in Cairo

Author's Department

Chemistry Department

Fifth Author's Department

Chemistry Department

Find in your Library

https://doi.org/10.1016/j.artmed.2025.103066

All Authors

Marwa Saady Mahmoud Eissa Ahmed S. Yacoub Ahmed B. Hamed Hassan Mohamed El Said Azzazy

Document Type

Research Article

Publication Title

Artificial Intelligence in Medicine

Publication Date

3-1-2025

doi

10.1016/j.artmed.2025.103066

Abstract

Introduction: There is a growing interest in leveraging artificial intelligence (AI) technologies to enhance various aspects of clinical trials. The goal of this systematic review is to assess the impact of implementing AI approaches on different aspects of oncology clinical trials. Methods: Pertinent keywords were used to find relevant articles published in PubMed, Scopus, and Google Scholar databases, which described the clinical application of AI approaches. A quality evaluation utilizing a customized checklist specifically adapted was conducted. This study is registered with PROSPERO (CRD42024537153). Results: Out of the identified 2833 studies, 72 studies satisfied the inclusion criteria. Clinical Trial Enrollment & Eligibility were among the most commonly studied clinical trial aspects with 30 papers. The prediction of outcomes was covered in 25 studies of which 15 addressed the prediction of patients' survival and 10 addressed the prediction of drug outcomes. The trial design was studied in 10 articles. Three studies addressed each of the personalized treatments and decision-making, while one addressed data management. The results demonstrate using AI in cancer clinical trials has the potential to increase clinical trial enrollment, predict clinical outcomes, improve trial design, enhance personalized treatments, and increase concordance in decision-making. Additionally, automating some areas and tasks, clinical trials were made more efficient, and human error was minimized. Nevertheless, concerns and restrictions related to the application of AI in clinical studies are also noted. Conclusion: AI tools have the potential to revolutionize the design, enrollment rate, and outcome prediction of oncology clinical trials.

Link to Full Text
Find this item online

Share

COinS